Lilly ' s Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions

INDIANAPOLIS, May 21, 2019 /PRNewswire/ -- In an oral presentation from the Digestive Disease Week medical conference in San Diego, California today, Eli Lilly and Company (NYSE: LLY) announced new safety and efficacy data for mirikizumab in...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials